ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway.

BACKGROUND: Epigenetic dysregulation constitutes one of the mechanisms in the pathogenesis of HCC, thereby underscoring its critical scientific importance for early diagnosis and therapeutic interventions. The chromatin remodeling factor AT-rich interaction domain 1A (ARID1A) serves as an essential epigenetic regulator and is frequently subject to inactivating mutations across various cancer types. Nevertheless, the precise molecular pathways by which ARID1A deficiency facilitates the progression of HCC remain inadequately elucidated. METHODS: RNA sequencing (RNA-seq) was employed to identify genes that were significantly upregulated following the knockdown of ARID1A. Immunohistochemistry was used to assess the expression levels of ARID1A and histone deacetylase 7 (HDAC7) in HCC samples. Chromatin immunoprecipitation and luciferase reporter assays were conducted to validate PU.1 as a positive transcriptional regulator of HDAC7. Protein immunoprecipitation coupled with mass spectrometry was used to identify potential substrates of HDAC7. A xenograft assay was performed to evaluate the therapeutic potential of HDAC7 inhibitors in ARID1A-deficient HCC. RESULTS: Our investigation demonstrated that the loss of ARID1A in HCC cells led to an upregulation of HDAC7 expression. Mechanistic analyses revealed that ARID1A deficiency facilitated PU.1-mediated transcriptional regulation of HDAC7. Additionally, the overexpression of HDAC7 resulted in a reduced acetylation level of Enolase 1 (ENO1), thereby enhancing the malignant proliferation of HCC cells. Targeting HDAC7 effectively inhibited the growth of ARID1A-deficient tumors in tumor-bearing mice. CONCLUSIONS: This study provides novel insights into the regulatory interplay between chromatin remodeling and acetylation modification, 2 pivotal epigenetic processes influencing tumorigenesis. It also suggests that pharmacological inhibition of HDAC7 offers a promising therapeutic strategy for treating HCC with ARID1A mutations.